Sifalimumab
Human monoclonal antibody
N
Y (what is this?) (verify) Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]
Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3][4][5]
References
- ^ Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B (January 2017). "Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus". Immunotherapy. 9 (1): 57–70. doi:10.2217/imt-2016-0090. PMID 28000522.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
- ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
- ^ "Sifalimumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 July 2017.
- ^ "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
